• DMXAA (Vadimezan, AS-1404): Mechanistic Insights and Stra...

  2025-09-30

  This thought-leadership article explores the intricate mechanistic landscape of DMXAA (Vadimezan, AS-1404) as a vascular disrupting agent and DT-diaphorase inhibitor, charting its unique position at the crossroads of tumor vasculature disruption, immune modulation, and endothelial STING-JAK1 signaling. By integrating evidence from recent high-impact studies, including novel insights into endothelial-driven antitumor immunity, the article provides translational researchers with strategic guidance on leveraging DMXAA in advanced cancer models. Contextualizing DMXAA within the evolving competitive and clinical landscape, the piece offers a visionary outlook on next-generation vascular and immune-targeted therapeutics—moving decisively beyond conventional product narratives.

• DMXAA (Vadimezan): Redefining Tumor Vasculature via STING...

  2025-09-29

  Explore how DMXAA (Vadimezan, AS-1404) serves as a vascular disrupting agent for cancer research, uniquely interfacing DT-diaphorase inhibition with emerging STING-JAK1 vascular normalization insights. Discover advanced mechanistic connections and future applications in tumor immunology.

• Paclitaxel (Taxol): Pioneering Microtubule Modulation in ...

  2025-09-28

  Explore how Paclitaxel (Taxol) acts as a microtubule polymer stabilizer, advancing cancer research and neuropathy modeling. This article uniquely integrates high-precision mechanistic insights with the latest in mRNA-based therapeutic interventions.

• Paclitaxel (Taxol): Microtubule Dynamics, Neuropathy Mode...

  2025-09-27

  Explore the unique role of Paclitaxel (Taxol) as a microtubule polymer stabilizer in cancer research and neuropathy modeling. This in-depth analysis highlights advanced insights into microtubule dynamics modulation and introduces innovative mRNA-based strategies for overcoming chemotherapy-induced peripheral neuropathy.

• Angiotensin II in Translational AAA Research: Pathways, B...

  2025-09-26

  Explore how Angiotensin II, a potent vasopressor and GPCR agonist, drives advanced research into abdominal aortic aneurysm (AAA) by integrating novel biomarker discovery, senescence mechanisms, and experimental modeling. This article delivers a unique perspective on angiotensin receptor signaling and translational research tools for vascular disease.

• DMXAA (Vadimezan): Unraveling Tumor Vasculature Disruptio...

  2025-09-25

  Explore how DMXAA (Vadimezan, AS-1404) acts as a vascular disrupting agent for cancer research by uniquely integrating DT-diaphorase inhibition, apoptosis induction in tumor endothelial cells, and the latest advances in STING-JAK1 signaling. This article provides a deep, mechanistic perspective on DMXAA’s translational potential in anti-angiogenic cancer therapy.

• DMXAA (Vadimezan): Unveiling Endothelial STING-JAK1 Cross...

  2025-09-24

  Explore how DMXAA (Vadimezan, AS-1404) uniquely modulates endothelial STING-JAK1 signaling to normalize tumor vasculature and enhance antitumor immunity. This in-depth analysis reveals novel mechanistic insights and advanced research strategies for cancer biology using this potent vascular disrupting agent.

• Angiotensin II in AAA Research: Linking GPCR Signaling to...

  2025-09-23

  Explore how Angiotensin II, a potent vasopressor and GPCR agonist, is driving new advances in understanding abdominal aortic aneurysm (AAA) through its impact on vascular smooth muscle cell hypertrophy and senescence-related pathways.

• DMXAA (Vadimezan

  2025-09-22

  This article examines the multifaceted role of DMXAA (Vadimezan, AS-1404) as a vascular disrupting agent for cancer research, emphasizing its dual activity as a DT-diaphorase inhibitor and apoptosis inducer in tumor endothelial cells. We explore recent insights into tumor vasculature normalization, anti-angiogenic mechanisms, and implications for enhancing antitumor immunity.

• DMXAA (Vadimezan): Translational Insights into Tumor Vasc...

  2025-09-19

  Explore how DMXAA (Vadimezan, AS-1404), a vascular disrupting agent and DT-diaphorase inhibitor, advances cancer biology research by targeting tumor vasculature and modulating immune responses. This review integrates recent findings on endothelial signaling and antitumor immunity.

• DMXAA (Vadimezan): Mechanisms and Research Applications i...

  2025-09-18

  Explore the mechanistic basis and research applications of DMXAA (Vadimezan, AS-1404), a vascular disrupting agent for cancer research. This article delves into DMXAA’s role as a DT-diaphorase inhibitor and apoptosis inducer in tumor endothelial cells, with a focus on tumor vasculature disruption and implications for cancer biology research.

• The proposed formulation is however challenging to solve sin

  2025-03-03

  

  The proposed formulation is, however, challenging to solve since the structured sparsity-inducing norms are non-smooth. In order to solve the new objective function, we consider two different approaches: proximal averaging, which takes the average the solutions from the proximal operator for the ind

• The only psychostimulant treatment option in Turkey is methy

  2025-03-03

  

  The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan

• Introduction Diabetic nephropathy is a rapidly growing cause

  2025-03-03

  

  Introduction Diabetic nephropathy is a rapidly growing cause of end-stage renal disease [1]. Glomerular, tubular and vascular toxicity resulting from hyperglycemia (glucotoxicity) have been evaluated extensively at the molecular level as contributing factors for diabetic nephropathy [[1], [2], [3]]

• br Functional consequences of ADK regulation on astrocyte fu

  2025-03-03

  

  Functional consequences of ADK regulation on astrocyte function As outlined above (see introduction), ADK critically regulates the extracellular adenosine levels in bcl-2 family (Boison, 2006, Etherington et al., 2009). Changes in the levels of adenosine, as a result of the regulation of ADK exp

7711 records 33/515 page Previous Next First page 上5页 3132333435 下5页 Last page